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Although not curative, androgen deprivation (AD) therapy is
presently the first treatment option for patients with recurrent
and/or metastatic prostate cancer [1]. Metastatic prostate can-
cer most frequently becomes resistant to continuous AD after
an average treatment time of 2 – 3 years [2]. Furthermore,
long-term AD may induce substantial side effects in patients
compromising general health status and quality of life includ-
ing cognitive and sexual impairment, fatigue, cardiovascular
dysfunction, metabolic syndrome, loss of lean body mass, and
osteoporosis [3–5]. Intermittent short courses of AD have
been proposed as an alternative to continuous AD and tested
in several phase II/III trials with the aim of reducing the
severity and duration of the above-mentioned side effects
and of delaying further the clinical appearance and progres-
sion of hormone-independent disease [6, 7]. However, these
trials have been unable to show a survival benefit of intermit-
tent compared to continuous AD. Nevertheless, substrata
analysis from a pre-PET/CT era randomized trial (RTOG 85-
31) that recruited patients between 1987 and 1992 and com-
pared continuous AD plus radiation with radiation alone in
patients with pathological node-positive adenocarcinoma of
the prostate showed 5-year biochemical control (i.e. PSA
<1.5 ng/ml) in 54 % of the combined treatment arm versus
33 % of the radiation-only arm [8]. The 9-year absolute
survival rate was 62 % in patients treated with combined
treatment [8]. In other words, patients with disease in the
pelvic or paraaortic lymph node regions treated with a com-
bination of AD and curative intent radiotherapy can expect
long-term survival despite their metastatic status.
A large majority of patients with early biochemical failure
after treatment of their primary tumour with curative intent
have no evidence of disease on standard imaging such as bone
scan or abdominal CT unless the PSA increases above
20 ng/ml [9]. PET/CT tracers for prostate cancer, including
11C-acetate, 11C-choline and 18F-choline, were developed
more than a decade ago and their role as reliable imaging tools
for assessing the extension of disease in patients with bio-
chemical failure in an earlier stage has slowly widened [10,
11]. Head-to-head comparisons of these three different tracers
are relatively scarce and frequently include only small num-
bers of patients. We have recently shown with PET/CT that
11C-acetate and 18F-choline produce very similar imaging
results in patients with early relapse of prostate cancer [12].
The relapse status of local, regional and distant sites can be
properly assessed with these imaging techniques so that the
salvage treatment approach can be optimized.
An oligometastatic status is not an uncommon clinical situ-
ation in patients with disseminated prostate cancer. Indeed,
Harada et al. observed a large proportion of patients with one
or twometastases in an autopsy series of 136 patients: 36% and
32 % of patients had one and two bone lesions, respectively
[13] . Only 10 % of patients had four or more bone metastases.
As mentioned above, it has been suggested that the number of
metastatic lesions in prostate cancer patients may be an impor-
tant prognosticator. Singh et al. reported that patients with up to
five metastases had a 5-year overall survival similar to
metastases-free patients and significantly better than patients
with more than five metastases (73 % versus 45 %) [14]. The
authors concluded that oligometastatic patients may harbour
tumours biologically less aggressive with limited metastatic
potential and a slow growth rate. These patients may be suitable
for more aggressive treatment approaches.
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Although PET/CT imaging techniques with choline or ace-
tate tracers are diagnostic procedures with a potentially higher
predictive value than CT and bone scans, their predictive value
in patients with low PSA levels (i.e. early relapse scenario) is
low. Indeed, during early progression PSAmaymost frequently
be below 4 ng/ml if the failure follows radiotherapy or far
below 1 ng/ml if the failure is detected after radical prostatec-
tomy. Such a low PSA level is limiting factor for the detection
of the suspected relapse site(s) even with choline or acetate
tracers. In a recent study in 156 patients with recurrent prostate
cancer after surgery or radiotherapy, PSA levels tended to be
significantly lower in patients with a negative PET/CT choline
study (median PSA 1.2 ng/ml, range 0.1 – 30.3 ng/ml) than in
those with a positive scan (median PSA 4.5 ng/ml, range
0.15 – 296.61 ng/ml) [15]. Scattoni et al. found a relatively
low sensitivity of 64 % for nodal metastases with 11C-choline
PET/CT imaging in patients with biochemical progression after
prostatectomy [16]. Delayed scanning with three-phase 18F-
choline PET/CT may improve the positive predictive value of
this investigation by better discriminating benign from suspi-
cious inflammatory lymph nodes [17].
Several authors have tried to use the tracing potential of
choline and/or acetate PET/CT studies to develop potentially
curative treatment strategies for patients with a limited number
of metastases. The use of surgery (targeted lymph node resec-
tion) or high-dose targeted radiotherapy most frequently com-
bined with AD has been described [18, 19]. In the present
issue of EJNMMI, Picchio et al. report on the potential value
of PET/CTcholine studies for optimizing treatment with high-
dose radiation beams of patients with metastatic lymph nodes
at relapse. In 42 of 47 patients (90 %) assessed with a PET/CT
examination after salvage irradiation they observed a com-
plete or partial metabolic response [20]. Considering the lim-
ited sensitivity of PET/CT choline studies, as mentioned
above, most of their patients were treated when feasible with
extended fields including the entire pelvic or paraaortic lymph
node region in the vicinity of the lymph nodes positive on
PET/CT, the latter receiving an additional boost dose [20].
Nonetheless, despite the good local response rates after
high-dose radiation or salvage lymph-node excision the report-
ed 3-year biochemical progression-free survival figures are
relatively modest (<30 – 40 %) [18, 19]. Only patients with a
limited number of metastases on PET/CT with choline or
acetate at first treatment or at relapse might be candidates for
an aggressive treatment strategy that combines limited duration
AD (9 – 12 months) with high-dose radiation (>64 Gy) to the
tracer positive metastatic lesions. Indeed, we have recently
reported on the treatment of patients with oligometastatic pros-
tate cancer (up to four sites) combining AD (median duration
12 months) with high-dose focused radiation to the metastatic
sites (lymph node and/or distant sites) detected with choline or
acetate PET/CT [21]. The 3-year biochemical-free survival
(PSA <1 ng/ml) and clinical failure-free survival in the 50
oligometastatic patients in this study were 54.5 % and
58.6 %, respectively. Furthermore, patients receiving a normal-
ized total dose of >64 Gy showed a significantly better
biochemical-free survival (65 % vs. 41.8 % for those receiving
≤64 Gy) in the multivariate analysis [21].
While the widely used choline tracers for prostate cancer
show good detection rates notably for local recurrences, they
appear less specific for lymph node and bone metastases.
Indeed, several groups have expressed doubts about the de-
tection of positive lymph node and bone metastases with
choline tracers probably because of potential uptake artefacts
caused by inflammatory reactions and degenerative bone dis-
ease, respectively. Research, notably at the preclinical level,
on new radiopharmaceuticals for the detection of prostate
cancer has been ongoing in recent years. Recently, the first
promising clinical results with bombesin [22–24] and PSMA
ligand [25–27] analogues have been reported. These two
tracers are among the top currently investigated tracers that
recognize gastrin-releasing peptides (GRP) and the PSMA
receptors identified in large amount and in a high percentage
of prostate cancers. The PSMA ligand MIP-1095
radiolabelled with 131I has already been used therapeutically,
and represents a new potential approach to the treatment of
disseminated prostate cancer [27].
In summary, despite limited sensitivity and specificity for
acetate and choline tracers, patients with oligometastatic pros-
tate cancer may benefit from targeted high-dose irradiation of
the suspected lesions associated with a short course of AD.
This hypothesis needs to be confirmed in a phase III trial
comparing intermittent AD with or without a complement of
targeted irradiation. Optimizing the local tumoricidal effect of
radiotherapy against gross disease will certainly not cure
patients with oligometastatic cancer but may prolong the
biochemical and clinical disease-free interval between AD
cycles, thus improving the limited efficacy of AD with good
quality overall survival. New upcoming tracers such as those
recognizing GRP and PSMA receptors may help in the future
to better assess the extension status of primary or recurrent
disease and to better tailor adapted strategies aiming to opti-
mize the potentially curative treatment of patients with
oligometastatic prostate cancer.
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